Not provided
Not provided
Not provided
Not provided
Not provided
lack of enrollment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This will be an open label phase 1b trial to characterize the pharmacodynamics and PK of prednisolone and SPI-62 when co-administered to participants with PMR. Up to 24 participants could be recruited.
This will be an open label phase 1b trial to characterize the pharmacodynamics and PK of prednisolone and SPI-62 when co-administered to participants with PMR. Up to 24 participants could be recruited.
Patients diagnosed with PMR whose PMR symptoms do not vary in intensity or frequency to the degree that a clinically indicated increase in prednisolone prescription might be anticipated will be included in the trial.
Participants will continue to receive prednisolone and will receive SPI-62 from Days 3-16
Inflammatory biomarkers, symptom measures, biomarkers of prednisolone toxicity, PK of prednisolone and SPI-62, and biomarkers of SPI-62 pharmacological activity will be measured on Days 2, 3, and 16. ABPM will be monitored on days 1 and 15.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| prednisolone + SPI-62 | Experimental | Participants will receive prednisolone throughout the trial and SPI-62 on days 3-16. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prednisolone | Drug | Prednisolone according to the participant's pre-trial dose, symptoms and inflammatory biomarkers. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Erythrocyte sedimentation rate | Baseline to Day 28 | |
| C-reactive protein | Baseline to Day 28 | |
| Plasma fibrinogen | Baseline to Day 28 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Katz | Sparrow Pharmaceuticals | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Emovis Gmbh | Berlin | Germany | ||||
| Klinische Forschung Hannover Mitte GmbH/Pratia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011111 | Polymyalgia Rheumatica |
| ID | Term |
|---|---|
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D003240 | Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D011239 | Prednisolone |
| ID | Term |
|---|---|
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| SPI-62 | Drug | SPI-62 administered once daily. |
|
| Hanover |
| 30159 |
| Germany |
| Universitätsmedizin der Johannes Gutenburg Universität Mainz | Mainz | 55131 | Germany |
| Klinikum der Universität München | München | 80336 | Germany |
| Klinische Forschung Schwerin GmbH/Pratia | Schwerin | 19055 | Germany |
| D017437 | Skin and Connective Tissue Diseases |
| D000072473 |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |